PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the House Committee on Energy and Commerce.
Congressional Research Service
Version 00 · Introduced in House · Feb 13, 2025
Prostate-Specific Antigen Screening for High-risk Insured Men Act or the PSA Screening for HIM Act
This bill requires private health insurance plans to cover evidence-based, preventive care and screenings for prostate cancer that are not already covered under the recommendations of the U.S. Preventive Services Task Force for certain men.
Specifically, plans must cover such care and screenings for men who are age 40 and over and are at high risk of developing prostate cancer (e.g., with a family history of prostrate cancer). Such coverage must be provided without imposing any cost-sharing requirement.
People & committees
Rep. Dunn, Neal P. [R-FL-2] · R–FL
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Sep 19, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1300 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1300 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1300 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1300 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-02-13 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
This proposal would require group health plans and insurers offering group or individual coverage to cover certain evidence-based prostate cancer preventive care and screenings without requiring patients to pay part of the cost. It would cover men age 40 and older at high risk, including African-American men and men with qualifying family histories. The requirement would apply to plan years beginning on or after January 1, 2026.
A group health plan and a health insurance issuer offering group or individual health insurance coverage shall, at a minimum, provide coverage for and shall not impose any cost-sharing requirements for—
(E) with respect to men who are age 40 and over and are at high risk of developing prostate cancer (including African-American men and men with a family history of prostate cancer (as defined in paragraph (2))), such additional evidence-based preventive care and screenings not described in subparagraph (A) for prostate cancer.
The amendment made by subsection (a) shall apply with respect to plan years beginning on or after January 1, 2026.
The bill’s findings describe higher prostate cancer risks for African-American men and men with family histories and call for reducing screening barriers. These are Congress’s stated reasons for the proposal, not evidence that the bill would achieve particular health outcomes.
Congress finds the following:
(5) African-American men have a disproportionately higher rate of prostate cancer and are 70 percent more likely to be diagnosed with prostate cancer than White men, with 1 in 6 African-American men developing prostate cancer in their lifetimes.
(7) Men with a father or brother with prostate cancer are more than twice as likely to be diagnosed with prostate cancer than men without a family history.
(11) Barriers to screening should be minimized for high-risk men in order to catch asymptomatic prostate cancer before it metastasizes and the survival rate is dramatically reduced.
The bill would replace subsection 2713(a) of the Public Health Service Act. Its prostate cancer coverage requirement would extend to additional evidence-based care and screenings beyond services with an A or B rating from the United States Preventive Services Task Force. African-American men and men with qualifying family histories are included examples of high-risk men, rather than an expressly exhaustive list.
Subsection (a) of section 2713 of the Public Health Service Act (42 U.S.C. 300gg–13) is amended to read as follows:
(A) evidence-based items or services that have in effect a rating of A or B in the current recommendations of the United States Preventive Services Task Force;
(E) with respect to men who are age 40 and over and are at high risk of developing prostate cancer (including African-American men and men with a family history of prostate cancer (as defined in paragraph (2))), such additional evidence-based preventive care and screenings not described in subparagraph (A) for prostate cancer.
Qualifying family history would include having a first-degree relative who was diagnosed with, developed, or died from prostate cancer. It would also include a first-degree relative diagnosed with a cancer associated with increased prostate cancer risk or having a genetic alteration associated with that increased risk.
For purposes of paragraph (1)(E), the term men with a family history of prostate cancer means men who have a first-degree relative— (A) who was diagnosed with prostate cancer; (B) who developed prostate cancer; (C) whose death was a result of prostate cancer; (D) who have been diagnosed with a cancer known to be associated with increased risk of prostate cancer; or (E) who has a genetic alteration known to be associated with increased risk of prostate cancer.
The replacement subsection would also require coverage without requiring patients to pay part of the cost for services rated A or B by the United States Preventive Services Task Force, recommended immunizations applicable to the individual, preventive care and screenings for infants through adolescents under specified federal guidelines, and additional women’s preventive care and screenings under specified federal guidelines.
A group health plan and a health insurance issuer offering group or individual health insurance coverage shall, at a minimum, provide coverage for and shall not impose any cost-sharing requirements for—
(A) evidence-based items or services that have in effect a rating of A or B in the current recommendations of the United States Preventive Services Task Force; (B) immunizations that have in effect a recommendation from the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention with respect to the individual involved; (C) with respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided for in the comprehensive guidelines supported by the Health Resources and Services Administration; (D) with respect to women, such additional preventive care and screenings not described in subparagraph (A) as provided for in comprehensive guidelines supported by the Health Resources and Services Administration for purposes of this subparagraph;
For breast cancer screening, mammography, and prevention, the replacement subsection would treat the most recent Task Force recommendations other than those issued in or around November 2009 as current. The language would apply for purposes of this Act and any other provision of law. The supplied sources do not establish whether this language changes or reproduces existing law.
For the purposes of this Act, and for the purposes of any other provision of law, the current recommendations of the United States Preventive Service Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than those issued in or around November 2009.
The replacement subsection could not be interpreted as prohibiting plans or insurers from covering services beyond Task Force recommendations or as denying coverage for services the Task Force does not recommend.
Nothing in this subsection shall be construed to prohibit a plan or issuer from providing coverage for services in addition to those recommended by the United States Preventive Services Task Force or to deny coverage for services that are not recommended by such Task Force.
The proposed amendment would apply by plan year: it specifies plan years beginning on or after January 1, 2026.
(b) Effective date The amendment made by subsection (a) shall apply with respect to plan years beginning on or after January 1, 2026.
The supplied action snapshot, updated September 19, 2026, records introduction in the House and referral to the House Committee on Energy and Commerce on February 13, 2025.
Source snapshot updated 2026-09-19T23:17:13Z. 2025-02-13: Referred to the House Committee on Energy and Commerce. 2025-02-13: Introduced in House
A closer look
Reviewed version: Introduced in House · 2025-02-13. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
Evidence is limited
Review of the complete supplied introduced text flags a possible unrelated provision, but the missing underlying law and attachment history prevent a definitive rider classification. This assessment is limited to the supplied version and does not establish the contents of other versions or accompanying materials.
Possible unrelated provision: the replacement subsection includes a rule excluding recommendations issued in or around November 2009 when determining current breast cancer screening, mammography, and prevention recommendations. That subject is distinct from the bill’s stated prostate screening focus, although it appears within the preventive-services subsection being replaced. Because the existing subsection is absent, the sources do not establish whether this rule is newly added or carried forward. The supplied evidence does not document its attachment history, so this is a tentative candidate, not a documented rider.
This Act may be cited as the Prostate-Specific Antigen Screening for High-risk Insured Men Act or the PSA Screening for HIM Act.
Subsection (a) of section 2713 of the Public Health Service Act (42 U.S.C. 300gg–13) is amended to read as follows:
For the purposes of this Act, and for the purposes of any other provision of law, the current recommendations of the United States Preventive Service Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than those issued in or around November 2009.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for particular recipients or places was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials. Member requests, disclosures, committee reports, and conference materials were not supplied, so formal earmark status cannot be independently established from those materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow preferential carve-out beyond ordinary coverage of the proposal’s intended beneficiaries was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials.
Full text preserved for this analysis. Legislative record snapshot: Sep 19, 2026. How PlainBill uses AI